Printer Friendly

Infinity Pharmaceuticals names new chief medical officer.

M2 EQUITYBITES-August 8, 2018-Infinity Pharmaceuticals names new chief medical officer

(C)2018 M2 COMMUNICATIONS http://www.m2.com

Infinity Pharmaceuticals Inc (NASDAQ: INFI), a biopharmaceutical company involved in advancing novel cancer treatments, announced yesterday that it has named Samuel Agresta, MD, MPH as its new chief medical officer.

In the new role, Dr Agresta will oversee global clinical development and regulatory affairs for the company.

Dr Agresta brings more than 20 years of experience in the practice of academic medicine and oncology drug development, including the recent approvals of two targeted therapies for the treatment of acute myeloid leukaemia. He joins Infinity from Agios Pharmaceuticals Inc, where he played a pivotal role in the development of the company's oncology programs, including two novel clinical oncology medicines, IDHIFA and TIBSOVO, as vice president and head of Clinical Development. Prior to Agios, Dr Agresta worked on the development of oncology therapeutics at Merrimack Pharmaceuticals and Genentech after spending ten years practicing academic medicine. He began his career at the Moffitt Cancer Center, where he served as associate medical director in the Sarcoma Oncology Unit.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Aug 8, 2018
Words:193
Previous Article:Universal declares dividend of USD0.75 per share for quarter.
Next Article:Jazz Pharmaceuticals reports Q2 2018 financial results.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters